Format
Items per page
Sort by

Send to:

Choose Destination

Results: 15

Related Articles by Review for PubMed (Select 18342223)

1.

Clopidogrel 600-mg double loading dose achieves stronger platelet inhibition than conventional regimens: results from the PREPAIR randomized study.

L'Allier PL, Ducrocq G, Pranno N, Noble S, Ibrahim R, Grégoire JC, Azzari F, Nozza A, Berry C, Doucet S, Labarthe B, Théroux P, Tardif JC; PREPAIR Study Investigators.

J Am Coll Cardiol. 2008 Mar 18;51(11):1066-72. doi: 10.1016/j.jacc.2007.12.013.

2.

Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.

Motovska Z, Kala P.

Clin Ther. 2008;30 Pt 2:2191-202. doi: 10.1016/j.clinthera.2008.12.001. Review.

PMID:
19281914
3.

[Optimal platelet inhibition after coronary stent implantation. Current status].

Silber S, Hoffmeister HM, Bode C.

Herz. 2008 Jun;33(4):244-53. doi: 10.1007/s00059-008-3138-9. Review. German.

PMID:
18581073
4.

High-dose clopidogrel loading in percutaneous coronary intervention.

Longstreth KL, Wertz JR.

Ann Pharmacother. 2005 May;39(5):918-22. Epub 2005 Apr 5. Review.

PMID:
15811910
5.

Meta-analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention.

Lotrionte M, Biondi-Zoccai GG, Agostoni P, Abbate A, Angiolillo DJ, Valgimigli M, Moretti C, Meliga E, Cuisset T, Alessi MC, Montalescot G, Collet JP, Di Sciascio G, Waksman R, Testa L, Sangiorgi G, Laudito A, Trevi GP, Sheiban I.

Am J Cardiol. 2007 Oct 15;100(8):1199-206. Epub 2007 Jul 30. Review.

PMID:
17920357
6.

Impact of pretreatment with clopidogrel on initial patency and outcome in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a systematic review.

Vlaar PJ, Svilaas T, Damman K, de Smet BJ, Tijssen JG, Hillege HL, Zijlstra F.

Circulation. 2008 Oct 28;118(18):1828-36. doi: 10.1161/CIRCULATIONAHA.107.749531. Epub 2008 Oct 13. Review.

7.

Antiplatelet therapy in percutaneous coronary intervention: integration of prasugrel into clinical practice.

Thomas D, Giugliano RP.

Crit Pathw Cardiol. 2009 Mar;8(1):12-9. doi: 10.1097/HPC.0b013e318196bb46. Review.

PMID:
19258833
8.

Platelet inhibition in percutaneous coronary interventions.

Wyss CA, Roffi M.

Herz. 2005 May;30(3):189-96. Review.

PMID:
15902369
9.

Contemporary issues on clopidogrel therapy.

Patti G, Di Sciascio G.

Intern Emerg Med. 2009 Jun;4(3):201-11. doi: 10.1007/s11739-008-0220-5. Epub 2009 Jan 8. Review.

PMID:
19130176
10.

Benefits of clopidogrel in patients undergoing coronary stenting significantly depend on loading dose: evidence from a meta-regression.

Biondi-Zoccai GG, Lotrionte M, Agostoni P, Valgimigli M, Abbate A, Sangiorgi G, Moretti C, Sheiban I.

Am Heart J. 2007 Apr;153(4):587-93. Review.

PMID:
17383298
12.

P2Y12 antagonism: promises and challenges.

Michelson AD.

Arterioscler Thromb Vasc Biol. 2008 Mar;28(3):s33-8. doi: 10.1161/ATVBAHA.107.160689. Epub 2008 Jan 3. Review.

13.

Clopidogrel resistance--the cardiologist's perspective.

Fefer P, Hod H, Matetzky S.

Platelets. 2007 May;18(3):175-81. Review.

PMID:
17497429
14.

[Place of ticlopidine in antiplatelet treatment].

Wlazłowski R, Goch A, Goch JH.

Pol Merkur Lekarski. 2005 Aug;19(110):131-5. Review. Polish.

PMID:
16245416
15.

Aspirin and clopidogrel resistance.

Fitzgerald DJ, Maree A.

Hematology Am Soc Hematol Educ Program. 2007:114-20. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk